Bora Pharmaceuticals is a pharmaceutical services provider operating under a dual-engine model that integrates contract development and manufacturing organization (CDMO) services with commercial pharmaceutical sales. The company specializes in formulation development, clinical and commercial manufacturing, and packaging for complex oral solid dose, liquid, semi-solid, biologic, and sterile injectable products. Its CDMO operations are supported by sites in North America and Asia, serving pharmaceutical and biotech partners globally. The commercial segment includes Upsher-Smith Laboratories, which manufactures and markets brand and generic pharmaceutical products in the U.S., and SunWay Biotech, which focuses on consumer healthcare solutions derived from microbial technologies. Bora also holds a strategic investment in Tanvex for biosimilar CDMO services and acquired MacroGenics’ GMP manufacturing operations in Maryland. Founded in 2007, the company serves markets in North America, Asia, and Europe, with a focus on niche and rare disease therapies in the U.S. market.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - Specialty & Generic Homepage bora-corp.com
Sector Healthcare IR page bora-corp.com/investors
Tags
cdmo, oral solid dose, sterile injectables, biologics, generic pharmaceuticals, consumer healthcare, biosimilars, rare disease, formulation development, packaging, Upsher-Smith Laboratories, SunWay Biotech, Bora Biologics, Eden Biologics, Yuta Health, TWi, Tanvex, MacroGenics, Lexapro, Lendormin, Dexlansoprazole DR, JAQBO
Press page —

Metrics

Valuation  
Market cap NT$ 39.674B
Market cap (USD) $ 1.204B
P/E 26.07
PEG 0.90
P/BV 2.51
P/S 1.87
P/OCF 40.45
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 21.1%
ROI 19.4%
ROIC 18.0%
Profit margin 15.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 28.9%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -25.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 19.014B 19.246B 14.2B 10.494B 4.9B 1.8B 1.529B 1.372B 357.823M 283.256M 237.652M 217.958M
Net profit 2.981B 3.939B 3.03B 1.392B 749.736M 578.426M 305.031M 442.843M 14.019M 24.571M 33.655M 16.601M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 488 752 639 — — — — — — — — —
Price performance 12m -0.35 0.18 — — — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Bora Pharmaceuticals Co., LTD. (ticker 6472.TW), listed in Taiwan.

ETFs Holding Bora Pharmaceuticals Co., LTD.

ETF Weight in ETF Shares Market value As of
RFEM 0.20% 13,228 $ 156.555K Jul 31, 2026
AVEE 0.06% 7,000 $ 76.715K Nov 16, 2026
DEXC 0.02% 5,000 $ 60.814K Nov 12, 2026
DFSE 0.01% 6,799 $ 82.695K Nov 12, 2026
DFEM 0.01% 88,309 $ 1.074M Nov 12, 2026
DFEV 0.01% 11,000 $ 133.79K Nov 12, 2026
DFAX 0.00% 43,456 $ 528.545K Nov 12, 2026
AVEM 0.00% 8,572 $ 93.943K Nov 16, 2026